Covid Vaccination Information

Vaccine Information

 

The NHS is currently offering the COVID-19 vaccine to people most at risk from coronavirus.

The vaccination is NOT recommended for anyone who has had COVID in the last 4 weeks or is pregnant.

The vaccine is currently available for:

· people aged 65 and over

· people aged 16-64 in an 'at risk' group (please see link below for full list of eligible conditions) people who live or work in care homes

· health and social care workers at high risk

The vaccine will be offered more widely as soon as possible in the following priority order:

· Residents in a care home for older adults and staff working in care homes for older adults

· All those 80 years of age and over and frontline health and social care workers

· All those 75 years of age and over

· All those 70 years of age and over and clinically extremely vulnerable individuals (not including pregnant women and those under 16 years of age)

· All those 65 years of age and over

· Adults aged 16 to 65 years in an at-risk group

· All those 60 years of age and over

· All those 55 years of age and over

· All those 50 years of age and over

· Rest of the population (to be determined)

Pfizer-BioNTech vaccine

The committee has reviewed published and unpublished Phase 1, 2 and 3 safety and efficacy data for the Pfizer BioNTech mRNA vaccine. The vaccine appears to be safe and well-tolerated, and there were no clinically concerning safety observations. The data indicates high efficacy in all age groups (16 years and over), including protection against severe disease and encouraging results in older adults. The committee advises that this vaccine be used in the first phase of the programme, according to the priority order set out below. While there is some evidence to indicate high levels of short-term protection from a single dose of vaccine, a 2-dose vaccine schedule is currently advised as this is likely to offer longer lasting protection.

AstraZeneca vaccine

The committee has reviewed published and unpublished Phase 1, 2 and 3 safety and efficacy data for the AstraZeneca vaccine. The vaccine appears to have a good safety profile, and the data indicates high efficacy in adults aged 18 years and over, including protection against severe disease and encouraging results in older adults. Existing data is consistent with high levels of short-term protection following the first dose of vaccine, with further protection obtained following the second dose of vaccine which may be given between 4 to 12 weeks after the first dose. The committee advises that this vaccine be used in the first phase of the programme, according to the priority order set out below. A 2-dose vaccine schedule is currently advised as this is likely to offer longer lasting protection.

The Pfizer-BioNTech vaccine is authorised in those aged 16 years and over. The AstraZeneca vaccine is only authorised for use in those aged 18 years and over.